Placebo Controlled, double-blind randomized controlled trial (RCT) with 12 months Tenofovir
Disoproxil and Raltegravir for primary biliary cholangitis (PBC) patients unresponsive to
Ursodeoxycholic Acid (UDCA). Placebo patients will be offered 12 months open label therapy at
unblinding. All patients will be offered an additional 12 months open label therapy.
Observational, open label study will be performed in parallel using Emtricitabine
(FTC)/Tenofovir Disoproxil (TDF) & Raltegravir in liver transplant recipients meeting all
entry criteria except for use of immunosuppression.